BMO Capital Markets Forecasts Strong Price Appreciation for Incyte (NASDAQ:INCY) Stock

Incyte (NASDAQ:INCY) had its price target increased by equities researchers at BMO Capital Markets from $112.00 to $130.00 in a report released on Wednesday,Benzinga reports. The firm presently has a “market perform” rating on the biopharmaceutical company’s stock. BMO Capital Markets’ target price would indicate a potential upside of 1.24% from the company’s previous close.

A number of other brokerages have also issued reports on INCY. HC Wainwright upped their price target on shares of Incyte from $140.00 to $150.00 and gave the company a “buy” rating in a research note on Wednesday. Guggenheim reissued a “buy” rating and set a $150.00 price objective on shares of Incyte in a report on Wednesday. UBS Group upped their target price on Incyte from $103.00 to $113.00 and gave the company a “neutral” rating in a research report on Friday, June 26th. Oppenheimer reissued a “market perform” rating and issued a $120.00 target price on shares of Incyte in a research report on Tuesday. Finally, Royal Bank Of Canada raised their target price on Incyte from $95.00 to $99.00 and gave the stock a “sector perform” rating in a research note on Tuesday, July 7th. Eight research analysts have rated the stock with a Buy rating and fourteen have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $116.50.

Incyte Stock Down 1.2%

NASDAQ INCY traded down $1.52 during trading on Wednesday, hitting $128.41. The company’s stock had a trading volume of 236,422 shares, compared to its average volume of 1,771,604. Incyte has a fifty-two week low of $73.81 and a fifty-two week high of $132.60. The company has a market cap of $25.65 billion, a PE ratio of 18.12, a P/E/G ratio of 1.03 and a beta of 0.76. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.68 and a quick ratio of 3.60. The business’s 50 day simple moving average is $107.99 and its 200-day simple moving average is $101.86.

Incyte (NASDAQ:INCY) last posted its quarterly earnings data on Tuesday, July 28th. The biopharmaceutical company reported $3.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.20 by $0.89. The firm had revenue of $1.67 billion for the quarter, compared to the consensus estimate of $1.50 billion. Incyte had a net margin of 26.71% and a return on equity of 26.66%. The company’s revenue for the quarter was up 37.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.57 earnings per share. On average, equities analysts anticipate that Incyte will post 6.9 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in INCY. Elyxium Wealth LLC purchased a new position in shares of Incyte in the 4th quarter valued at about $28,000. Smithfield Trust Co boosted its position in Incyte by 135.0% during the fourth quarter. Smithfield Trust Co now owns 282 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 162 shares in the last quarter. University of Texas Texas AM Investment Management Co. acquired a new stake in Incyte in the fourth quarter valued at approximately $35,000. Atlas Capital Advisors Inc. acquired a new stake in Incyte in the fourth quarter valued at approximately $35,000. Finally, Leonteq Securities AG purchased a new stake in shares of Incyte in the fourth quarter valued at approximately $35,000. Hedge funds and other institutional investors own 96.97% of the company’s stock.

Key Headlines Impacting Incyte

Here are the key news stories impacting Incyte this week:

• Positive Sentiment: Q2 results exceeded expectations: Revenue rose 38% year over year to $1.67 billion, while adjusted EPS of $3.09 surpassed the $2.20 consensus estimate. Total net sales increased 40% to $1.49 billion. Incyte quarterly earnings report
• Positive Sentiment: 2026 guidance was raised: Incyte now expects total net sales of $5.13 billion to $5.26 billion, up from its prior $4.77 billion to $4.94 billion forecast. Opzelura guidance increased to $1.05 billion-$1.10 billion following a CMS settlement.
• Positive Sentiment: Broad portfolio growth strengthened the outlook: Jakafi sales rose 7% to $817 million, Opzelura sales surged 173% to $450 million, and the Hematology and Oncology portfolio grew 69% to $222 million. The CMS agreement includes an estimated $300 million-$310 million 2026 Opzelura benefit, including a $246 million one-time non-cash contribution. Ten clinical readouts, including four registrational trials, are expected in the second half of 2026. Incyte Q2 outlook analysis
• Neutral Sentiment: Analyst views are mixed: HC Wainwright raised its Buy price target from $140 to $150, while UBS reiterated Hold with a $113 target, suggesting the recent rally may have limited near-term upside according to UBS.
• Negative Sentiment: Valuation and execution risks remain: Several analysts’ targets remain below the current market level, and Incyte discontinued an early-stage JAK inhibitor program to focus on next-generation candidates. Reported insider activity also showed selling without purchases over the past six months, though such transactions may not reflect management’s current business outlook.

About Incyte

Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company’s research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.

The company’s flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.